Is increasing the dose of Entecavir effective in partial virological responders?
Authors Erturk A, Akdogan RA, Parlak E, Cure E, Cumhur Cure M, Ozturk C
Received 20 January 2014
Accepted for publication 20 March 2014
Published 29 May 2014 Volume 2014:8 Pages 621—625
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Ayse Erturk,1 Remzi Adnan Akdogan,2 Emine Parlak,3 Erkan Cure,2 Medine Cumhur Cure,4 Cinar Ozturk1
1Department of Infectious Diseases, 2Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey; 3Department of Infectious Diseases, School of Medicine, Ataturk University, Erzurum, Turkey; 4Department of Biochemistry, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey
Objective: To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year.
Methods: Twenty-three hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients with CHB were treated with ETV 0.5 mg daily. After 1 year of the treatment, those with detectable hepatitis B virus (HBV-DNA) were randomized to either ETV 0.5 mg or 1 mg daily. The resistance to ETV was excluded. Both groups received ETV for 3 years. The groups were compared in aspects of undetectable DNA.
Results: Group 1 was given 0.5 mg ETV and included 32 patients (20 HBeAg-negative and 12 HBeAg-positive). Group 2 was given 1 mg ETV and consisted of 27 patients (16 HBeAg-negative and eleven HBeAg-positive). Group 2 had more effective suppression of HBV-DNA while both groups had comparable rates of HBeAg loss (58% and 63% for group 1 and group 2, respectively) and alanine transaminase (ALT) normalization at the end of 4 years.
Conclusion: Increasing ETV dose from 0.5 mg to 1 mg after 1 year of ETV treatment may provide an effective suppression of viral replication.
Keywords: chronic hepatitis B, treatment, entecavir, treatment, patient monitoring
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]